129 related articles for article (PubMed ID: 9845393)
21. Reports prompt new warnings on LMW heparins, heparinoids.
Am J Health Syst Pharm; 1998 Feb; 55(3):210. PubMed ID: 9492250
[No Abstract] [Full Text] [Related]
22. Food and Drug Administration update. The MedWatch program.
White GG; Love L
J Toxicol Clin Toxicol; 1998; 36(1-2):145-9. PubMed ID: 9541064
[No Abstract] [Full Text] [Related]
23. Evaluating the completeness and accuracy of MedWatch data.
Getz KA; Stergiopoulos S; Kaitin KI
Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
[TBL] [Abstract][Full Text] [Related]
24. Postmarketing surveillance: beyond MEDWatch.
Faich GA
JAMA; 1993 Nov; 270(18):2180. PubMed ID: 8411596
[No Abstract] [Full Text] [Related]
25. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
Kessler DA
J Am Podiatr Med Assoc; 1994 Jan; 84(1):35-8. PubMed ID: 8295131
[No Abstract] [Full Text] [Related]
26. MedWatch: the FDA medical products reporting program.
Rheinstein PH
Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
[No Abstract] [Full Text] [Related]
27. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
Kessler DA
Gen Hosp Psychiatry; 1994 Mar; 16(2):96-101; discussion 102. PubMed ID: 8039699
[No Abstract] [Full Text] [Related]
28. MedWatch: the new medical products reporting program.
Couig MP; Merkatz RB
Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
[No Abstract] [Full Text] [Related]
29. A one-year perspective on MedWatch: the Food and Drug Administration's new medical products reporting program.
Gruchalla RS
J Allergy Clin Immunol; 1995 Jun; 95(6):1153-7. PubMed ID: 7797782
[No Abstract] [Full Text] [Related]
30. Spinal/epidural haematomas associated with neuraxial anaesthesia in the presence of heparin and low-molecular-weight heparins.
Payne K; Mehta U
S Afr Med J; 2000 Jun; 90(6):604. PubMed ID: 10918889
[No Abstract] [Full Text] [Related]
31. MedWatch: FDA's Medical Products Reporting Program.
Goldman SA; Kennedy DL
Postgrad Med; 1998 Mar; 103(3):13-6. PubMed ID: 9519028
[No Abstract] [Full Text] [Related]
32. Drug recalls and notification of practitioners.
Rodts MF
Orthop Nurs; 2004; 23(6):353-4. PubMed ID: 15682877
[No Abstract] [Full Text] [Related]
33. New thoughts on the "forgotten" aspect of antimicrobial stewardship: adverse event reporting.
Hoffmann C; Khadem T; Schweighardt A; Brown J
Pharmacotherapy; 2015 Jan; 35(1):59-63. PubMed ID: 25615401
[TBL] [Abstract][Full Text] [Related]
34. Spinal epidural hematoma following epidural anesthesia versus spontaneous spinal subdural hematoma. Two case reports.
Metzger G; Singbartl G
Acta Anaesthesiol Scand; 1991 Feb; 35(2):105-7. PubMed ID: 1850945
[TBL] [Abstract][Full Text] [Related]
35. Pharmacovigilance: Importance, concepts, and processes.
Kumar A
Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
[No Abstract] [Full Text] [Related]
36. Vaccine adverse event reporting: the importance of follow-up.
Varricchio F
Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
[No Abstract] [Full Text] [Related]
37. MedWatch. FDA's 'heads up' on medical product safety.
Henkel J
FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445
[No Abstract] [Full Text] [Related]
38. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
39. Spinal-epidural hematoma following epidural anesthesia in the presence of antiplatelet and heparin therapy.
Litz RJ; Hübler M; Koch T; Albrecht DM
Anesthesiology; 2001 Oct; 95(4):1031-3. PubMed ID: 11605904
[No Abstract] [Full Text] [Related]
40. Postmarketing surveillance and reporting of adverse drug events.
Baer RK
S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
